XI-006 induces potent p53-independent apoptosis in Ewing sarcoma

There is an imperious need for the development of novel therapeutics for the treatment of Ewing sarcoma, the second most prevalent solid bone tumour observed in children and young adolescents. Recently, a 4-nitrobenzofuroxan derivative, XI-006 (NSC207895) was shown to diminish MDM4 promoter activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Pishas, Kathleen I., Adwal, Alaknanda, Neuhaus, Susan J., Clayer, Mark T., Farshid, Gelareh, Staudacher, Alexander H., Callen, David F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476092/
https://www.ncbi.nlm.nih.gov/pubmed/26095524
http://dx.doi.org/10.1038/srep11465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476092/
https://www.ncbi.nlm.nih.gov/pubmed/26095524
http://dx.doi.org/10.1038/srep11465

Ejemplares similares